{
    "root": "fb8ba940-aef7-d17f-6539-6f3a73ae3a72",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Insulin Glargine",
    "value": "20250303",
    "ingredients": [
        {
            "name": "INSULIN GLARGINE",
            "code": "2ZM8CX04RZ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_145810"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "METACRESOL",
            "code": "GGO4Y809LO"
        },
        {
            "name": "ZINC CHLORIDE",
            "code": "86Q357L16B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17996"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53424"
        }
    ],
    "indications": {
        "text": "insulin glargine-yfgn indicated improve glycemic control adult pediatric patients diabetes mellitus . limitations insulin glargine-yfgn recommended treatment diabetic ketoacidosis .",
        "doid_entities": [
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            },
            {
                "text": "diabetic ketoacidosis (DOID:1837)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1837"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 individualize based metabolic needs , blood glucose monitoring , glycemic control , type diabetes , prior insulin . ( 2.2 ) \u2022 administer subcutaneously abdominal area , thigh , deltoid daily time day , time every day . ( 2.1 ) \u2022 dilute mix insulin solution . ( 2.1 ) \u2022 rotate injection sites reduce risk lipodystrophy localized cutaneous amyloidosis . ( 2.1 ) \u2022 full prescribing information recommended starting patients type 2 diabetes ( 2.3 ) change insulin glargine-yfgn insulins . ( 2.4 ) \u2022 closely monitor glucose switching insulin glargine-yfgn initial weeks thereafter . ( 2.4 )",
        "doid_entities": [
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            },
            {
                "text": "lipodystrophy (DOID:811)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_811"
            },
            {
                "text": "amyloidosis (DOID:9120)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9120"
            },
            {
                "text": "type 2 diabetes (DOID:9352)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9352"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "insulin glargine-yfgn contraindicated : \u2022during episodes hypoglycemia [ ( 5.3 ) ] \u2022in patients hypersensitivity insulin glargine products excipients insulin glargine-yfgn [ ( 5.5 ) ]",
    "indications_original": "Insulin Glargine-yfgn is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.\n                  \n                     Limitations of Use\n                  \n                  Insulin Glargine-yfgn is not recommended for the treatment of diabetic ketoacidosis.",
    "contraindications_original": "\u2022 Individualize dosage based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use. ( 2.2 ) \u2022 Administer subcutaneously into the abdominal area, thigh, or deltoid once daily at any time of day, but at the same time every day. ( 2.1 ) \u2022 Do not dilute or mix with any other insulin or solution. ( 2.1 ) \u2022 Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis. ( 2.1 ) \u2022 See Full Prescribing Information for the recommended starting dosage in patients with type 2 diabetes (2.3) and how to change to Insulin Glargine-yfgn from other insulins. ( 2.4 ) \u2022 Closely monitor glucose when switching to Insulin Glargine-yfgn and during initial weeks thereafter. ( 2.4 )",
    "adverseReactions_original": "Insulin Glargine-yfgn is contraindicated:\n                  \n                     \n                        \u2022During episodes of hypoglycemia [see Warnings and Precautions (5.3)]\n                     \n                     \n                        \u2022In patients with hypersensitivity to insulin glargine products or any of the excipients in Insulin Glargine-yfgn [see Warnings and Precautions (5.5)]",
    "drug": [
        {
            "name": "Insulin Glargine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_145810"
        }
    ]
}